Anafiltamig
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
For research use only. We do not sell to patients.
- CAS No.: 3009026-69-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3-(scFv-kappa-heavy)
Human
CD79B & CD3E &CD20/MS4A1
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
half-G1-kappa_scFvlh-h-CH2-CH3-scFvkh
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 3009026-69-8
-
SMILES
N/A
-
Synonyms
JNJ-80948543
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz